Results 1 to 10 of about 16,494 (203)

Probenecid, an Old Drug with Potential New Uses for Central Nervous System Disorders and Neuroinflammation

Biomedicines, 2023
Probenecid is an old uricosuric agent used in clinics to treat gout and reduce the renal excretion of antibiotics. In recent years, probenecid has gained attention due to its ability to interact with membrane proteins such as TRPV2 channels, organic ...
Juan C Sáez, Arlek M Gonzalez-Jamett, Alvaro O Ardiles   +2 more
exaly   +4 more sources

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19

Viruses, 2023
Probenecid is an orally bioavailable, uricosuric agent that was first approved in 1951 for the treatment of gout, but was later found to have potent, broad-spectrum antiviral activity against several respiratory viruses including SARS-CoV-2. We conducted
David E. Martin, Neelam Pandey, Purvi Chavda, Gurpreet Singh, Rakesh Sutariya, Frederic Sancilio, Ralph A. Tripp   +6 more
doaj   +2 more sources

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib

Pharmaceutics, 2020
Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases sorafenib uptake in skin and might, therefore, decrease sorafenib-induced cutaneous adverse
Koen G. A. M. Hussaarts, Leni van Doorn, Karel Eechoute, Jeffrey Damman, Qiang Fu, Nadia van Doorn, Eric D. Eisenmann, Alice A. Gibson, Esther Oomen-de Hoop, Peter de Bruijn, Sharyn D. Baker, Stijn L. W. Koolen, Teun van Gelder, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen, Alex Sparreboom, Sander Bins   +16 more
doaj   +2 more sources

Blockade of Organic Anion Transport in Humans After Treatment With the Drug Probenecid Leads to Major Metabolic Alterations in Plasma and Urine

Clinical Pharmacology and Therapeutics, 2022
Probenecid is used to treat gout and hyperuricemia as well as increase plasma levels of antiviral drugs and antibiotics. In vivo, probenecid mainly inhibits the renal SLC22 organic anion transporters OAT1 (SLC22A6), OAT3 (SLC22A8), and URAT1 (SLC22A12 ...
Jeffry C Granados, Sanjay K Nigam
exaly   +2 more sources

Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy.

PLoS ONE, 2020
Probenecid has been used for decades in the treatment of gout but recently has also been found to improve outcomes in patients with heart failure via stimulation of the transient receptor potential vanilloid 2 (TRPV2) channel in cardiomyocytes.
Evan Onusko, Michael R McDermott, Nathan Robbins, Guansheng Liu, Evangelia G Kranias, Jack Rubinstein, Sheryl E Koch   +6 more
doaj   +2 more sources

Evaluation of the Safety and Pharmacokinetics of Single‐Dose Oral Probenecid Administration in Healthy Dogs [PDF]

Journal of Veterinary Internal Medicine
Background Grape‐induced acute kidney injury (AKI) is caused by tartaric acid and may lead to death in dogs. Probenecid, an organic anion transporter‐1 inhibitor, recently has been shown to block the uptake of tartaric acid in Madin–Darby canine kidney ...
Margaret Cook, Daniel L. Gustafson, Katie Kroeker, Sarah Shropshire, Kristin M. Zersen   +4 more
doaj   +2 more sources

Probenecid-Blocked Pannexin-1 Channel Protects Against Early Brain Injury via Inhibiting Neuronal AIM2 Inflammasome Activation After Subarachnoid Hemorrhage

Frontiers in Neurology, 2022
AimPrevious studies have proved that inhibiting inflammasome activation provides neuroprotection against early brain injury (EBI) after subarachnoid hemorrhage (SAH), which is mainly focused on the microglial inflammatory response, but the potential role
Yonghe Zheng, Wenwen Tang, Hanhai Zeng, Yucong Peng, Xiaobo Yu, Feng Yan, Shenglong Cao   +6 more
doaj   +2 more sources

Pharmacological mechanisms of probenecid for SARS-CoV-2 and RSV co-infection: findings of system pharmacology, molecular docking, molecular dynamics simulation, and structure–activity relationship [PDF]

Frontiers in Microbiology
BackgroundThe clinical consequences of the co-infection with novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and respiratory syncytial virus (RSV) are not optimistic.
Junbin Hong, Zhendong Guo, XiaoMei Huang, Peng Wu, Xinying Chen, Xiaoyi Liu, Jinghua Yang, Yanni Lai   +7 more
doaj   +2 more sources

Effects of Acute Probenecid Administration on Histopathological and Functional Outcomes after Spinal Cord Injury in Rats [PDF]

Neurotrauma Reports
Spinal cord injury (SCI) triggers an inflammatory response that is partially mediated by the inflammasome and the production of pro-inflammatory cytokines.
Toru Asari, Sunao Tanaka, Damien D. Pearse, Juan Pablo de Rivero Vaccari, Toshitada Sawada, Yasuyuki Ishibashi, Robert W. Keane, W. Dalton Dietrich   +7 more
doaj   +2 more sources

Probenecid

JACC: Case Reports, 2019
A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy.
Evan C. Klein, MD, Jack Rubinstein, MD, Jennifer L. Strande, MD, PhD   +2 more
doaj   +2 more sources